Recent News

• 04.11.2025 - FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean
• 04.08.2025 - FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics
• 04.02.2025 - FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair
• 03.31.2025 - FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update
• 03.27.2025 - FibroBiologics Announces 2025 Annual Meeting of Stockholders
• 03.21.2025 - FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting
• 03.04.2025 - FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics
• 02.27.2025 - FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic
• 02.05.2025 - FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates

Recent Filings

• 04.11.2025 - PRE 14A Other preliminary proxy statements
• 03.31.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.12.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.10.2025 - EFFECT Notice of Effectiveness
• 02.07.2025 - 8-K Current report
• 02.06.2025 - CORRESP Correspondence
• 02.06.2025 - UPLOAD SEC-generated letter